group, while APO-negative group exhibited moderate ED. We analyzed global gene expression in APO-positive group and APOnegative group, and focused on same changing trend within groups. In microarray analysis, 16 candidate genes were noted to be altered based on magnitude of expression changes, which includes 1 step up-regulated and 15 step down-regulated genes compared with the age matched normal controls. In vivo experiment exhibited erectile function in AAV-S100A1 group was markedly increased in the diabetic rats compared with the AAV-GFP groups. Mechanistically, S100A1 supplementation enhanced NO-cGMP and upstream VEGFR2/Akt signaling pathway. Consistented with in vivo experiments, in vitro study confirmed S100A1 compromised endothelial nitric oxide synthase (eNOS) activity in ECs by triggered the rapid cellular internalization of VEGFR2 and activated protein kinase C (PKC) hyperactivation which was blocked in the peresence of Calphostin-C. Moreover, transfection of AECs with small interfering RNA (siRNA) targeting either PKCa, d, or ε confirmed that by regulating VEGFR2 expression and activation, PKC ε expression is critical for activation of Akt and eNOS by S100A1.
group, while APO-negative group exhibited moderate ED. We analyzed global gene expression in APO-positive group and APOnegative group, and focused on same changing trend within groups. In microarray analysis, 16 candidate genes were noted to be altered based on magnitude of expression changes, which includes 1 step up-regulated and 15 step down-regulated genes compared with the age matched normal controls. In vivo experiment exhibited erectile function in AAV-S100A1 group was markedly increased in the diabetic rats compared with the AAV-GFP groups. Mechanistically, S100A1 supplementation enhanced NO-cGMP and upstream VEGFR2/Akt signaling pathway. Consistented with in vivo experiments, in vitro study confirmed S100A1 compromised endothelial nitric oxide synthase (eNOS) activity in ECs by triggered the rapid cellular internalization of VEGFR2 and activated protein kinase C (PKC) hyperactivation which was blocked in the peresence of Calphostin-C. Moreover, transfection of AECs with small interfering RNA (siRNA) targeting either PKCa, d, or ε confirmed that by regulating VEGFR2 expression and activation, PKC ε expression is critical for activation of Akt and eNOS by S100A1.
CONCLUSIONS: Microarray analysis identified 82 diabeticrelated molecular alterations. Among them, S100A1 was significantly step-down regulated. S100A1 supplementation improves erectile function in rats with DED probably by its pro-angiogenic effects that associated with the increased expression, internalization of VEGFR2 and PKC ε hyperactivation. These finding provides evidence for a potential new target for DED management. METHODS: Human penile resistance arteries (HPRA) and corpus cavernosum (HCC) were dissected from cavernosal specimens from 15 organ donors (OD) without history of ED and from 20 ED patients undergoing penile prosthesis insertion and functionally evaluated in wire myographs and organ chambers, respectively. One or more cardiovascular risk factors were present in all ED patients. Immunofluorescence was used for localization and quantification STIM-1, Orai1 and Orai3 expression in HCC.
RESULTS: Norepinephrine (NE)-induced contractions were significantly reduced by inhibition of Orai channels with YM-58483 (20 mM) in both HCC and HPRA from either OD or ED subjects. However, these the effects were more marked in ED (19.1AE9.1% vs.47.3AE13.1% and 11.5AE2.8% vs.28.7AE2.7% reduction in Emax to NE in HCC and HPRA, respectively). Orai inhibitor also reduced thromboxane-and KCl-induced contractions of penile tissues. In fact, addition of YM-58483 concentration-dependently relaxed precontracted HPRA and HCC. These relaxations were significantly more pronounced in tissues from ED patients (EC50 7.5 vs. 1.3 mM and 10.5 vs. 1.3 mM, for HCC and HPRA, respectively). Expression of STIM-1, Orai1 and Orai3 was detected in HCC from all subjects.
Increased expression of Orai1 (+47.5AE10.1) and Orai3 (+82.2AE14.4%, p<0.05) but not STIM-1 was detected in HCC from ED patients.
CONCLUSIONS: STIM/Orai system plays a relevant role in penile smooth muscle contraction in ED. This fact suggests that STIM/ Orai could be a potential therapeutic strategy to reduce penile contractile tone in ED.
Source of Funding: Instituto de Salud Carlos III (MINECO, Spanish Government, PI15/00674, PI15/01160, PI15/01969) and FEDER funds.
MP43-09 EFFECTS OF PLATELET RICH PLASMA ON IMPROVING ERECTILE DYSFUNCTION IN STREPTOZOTOCIN-INDUCED DIABETIC RATS
ChunHou Liao*, YiNo Wu, HanSun Chiang, New Taipei City, Taiwan INTRODUCTION AND OBJECTIVES: Platelet rich plasma (PRP) has shown to prevent the atrophy of corporal smooth muscle cell and enhance the regeneration of nerve fiber in cavernous nerve injury rat model. In this study, we investigate the effects of PRP on recovery of erectile dysfunction in streptozotocin (STZ) -induced diabetic rats.
METHODS: Six-week-old SD male rats received intraperitoneal (IP) injection of STZ (65mg/kg) or vehicle injection after a 16 hour fast. Twelve weeks later, the erectile function in the entire rat was assessed by measuring intracavernosal pressure (ICP) and other functional parameters of erectile function. Diabetics with erectile dysfunction (ED) rat were divided into two groups: the intracavernosal (IC) injection vehicleonly or PRP treatment. The control without STZ injection and diabetic rat without ED were as a control. Four weeks after treatment, erectile function was assessed by measuring ICP. Penile tissues were collected to undergoing the histomorphometrically analyzed and further perform ultrastructural analysis of the corpus cavernosum.
RESULTS: PRP treated group increased all erectile function parameters at 28 day post-treatment. Ultrastructural analysis revealed PRP improving erectile dysfunction of diabetic rats is through tissueprotective effect to keep integrity the corpus cavernosum.
CONCLUSIONS: PRP treatment improved erectile function in STZ-induced diabetic rats through protection of corpus cavernosum. PRP may have the potential for clinical use of diabetes with ED. It can provide another way for the treatment of ED with diabetic.
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